Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03482791 · ClinicalTrials.gov registry record · NA
Proton Beam Therapy in the Treatment of Esophageal Cancer
A NA study of Esophageal Cancer and Esophagus Cancer, sponsored by Washington University School of Medicine.
- Active
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT03482791: Active NA study of Esophageal Cancer and Esophagus Cancer, sponsored by Washington University School of Medicine.
NCT03482791 is a NA study of Esophageal Cancer and Esophagus Cancer that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 22 participants, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03482791, a NA study of Esophageal Cancer and Esophagus Cancer, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators plan to include both operable and inoperable patients with esophagus cancer in this prospective trial. Since both proton and photon treatments are biologically equivalent, the investigators do not expect a difference in tumor control compared to intensity modulated radiation therapy (IMRT). The investigators have a prospective experience of physician-reported toxicity and patient outcome using IMRT for patients with inoperable esophagus cancer that will serve as a comparison group. For the resectable patients receiving trimodality therapy (chemoradiation followed by surgery), the investigators will carefully track toxicity and patient outcomes prospectively. The central hypothesis is that the biologic efficacy for tumor control should be similar between protons and photons, and therefore survival measures should be similar between the two groups, but that the main difference lies in the total severe toxicities experienced by the patients undergoing therapy.
Primary Outcome
The MDASI-Plus is a reliable, validated tool for assessing cancer-related symptoms regardless of therapy or specific cancer diagnosis. Patients are asked to fill out a twenty-seven question inventory. 21 questions ask the patient about the severity of their symptoms with answers ranging from 0=not present to 10=as bad as you can imagine. 6 questions ask the patient about how their symptoms interfered with their life with answers ranging from 0=did not interfere to 10=interfered completely. The h
Conditions Studied
Interventions
- RADIATION Proton beam therapy
- OTHER Patient-Reported Outcome Measures
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-04-19 |
| Est. Completion | 2026-08-09 |
| Phase | NA |
What the registry record for NCT03482791 still lists
NCT03482791 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Proton beam therapy is the first listed.
NCT03482791 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT03482791 about?
NCT03482791 is a clinical study titled "Proton Beam Therapy in the Treatment of Esophageal Cancer". The investigators plan to include both operable and inoperable patients with esophagus cancer in this prospective trial. Since both proton and photon treatments are biologically equivalent, the investigators do not expect a difference in tumor control compared to intensity modulated radiation therap...
What is the current status of trial NCT03482791?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 22 participants. The study started on 2018-04-19. Estimated completion is 2026-08-09.
What conditions does trial NCT03482791 study?
This clinical trial studies the following conditions: Esophageal Cancer, Esophagus Cancer, Cancer of the Esophagus.
What interventions are being tested in trial NCT03482791?
The interventions under investigation include: Proton beam therapy (RADIATION), Patient-Reported Outcome Measures (OTHER).
Who is sponsoring clinical trial NCT03482791?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03482791 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03482791's enrollment target sits among peer trials
22 107th of 123 higher than 16 of 123 other Esophageal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
RECRUITING · NA
-
Exercise Prehabilitation for Locoregional Esophageal Cancer
RECRUITING · NA
-
Resilience and Equity in Aging, Cancer, and Health (REACH)
RECRUITING · NA
-
Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus
RECRUITING · NA
-
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
RECRUITING · NA
-
Serial MRI Scans During Radiation Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI